Skip to main content

Counterfeit Version of Adderall Unsafe, Ineffective, FDA Warns


May 30, 2012 — A counterfeit version of Adderall (Teva Pharmaceutical Industries) 30 mg tablets being sold on the Internet is unsafe, ineffective, and potentially harmful, the US Food and Drug Administration (FDA) warns.
The FDA's preliminary laboratory tests show that the counterfeit tablets contain the wrong active ingredients. Adderall contains dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amephtamine sulfate. In contrast, the counterfeit medication was found to contain tramadol and acetaminophen.
Currently on the FDA's drug shortage list, Adderall is in short supply owing to active pharmaceutical ingredient supply issues. Teva continues to release product as it becomes available. The FDA warns that "consumers should be extra cautious when buying their medicines from online sources. Rogue Web sites and distributors may especially target medicines in short supply for counterfeiting."
The counterfeit Adderall tablets are round, white, and do not have any markings. The FDA has posted a link to photos of the counterfeit pills and notes that any product that resembles the tablets or packaging and claims to be Adderall 30 mg pill should be considered counterfeit.
In contrast, authentic Adderall 30 mg tablets produced by TEVA are round and orange/peach in color, with "dp" embossed on one side of the tablet and "30" on the other side. Teva's Adderall 30 mg tablets are packaged only in a 100-count bottle with the National Drug Code (NDC) 0555-0768-02 listed.
The Adderall 30 mg product may be counterfeit if:
  1. The product comes in a blister package.
  2. There are misspellings on the package.
    • "NDS" appears instead of "NDC."
    • "Aspartrte" appears instead of "Aspartate."
    • "Singel" appears instead of "Single."
  3. The tablets are white in color, round in shape, and are smooth.
  4. The tablets have no markings on them.
Anyone who believes they have the counterfeit version of Teva's Adderall 30 mg tablets should not take or should stop taking the product. Consumers should talk to their healthcare professional about their condition and options for treatment.
Consumers and healthcare professionals are encouraged to report adverse events or side effects from the suspect counterfeit Adderall to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
  • Complete and submit the report online: www.fda.gov/MedWatch/report.htm.
  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.
Consumers who believe they have received counterfeit Adderall should contact the FDA's Office of Criminal Investigations (OCI) at 800-551-3989 or http://www.fda.gov/OCI.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

Obama Renominates Tavenner to Be CMS Chief

President Barack Obama yesterday renominated Marilyn Tavenner, the acting administrator of the Centers for Medicare & Medicaid Services (CMS), to serve in that post without the caveat of "acting" attached to it. If the Senate approves her nomination, Tavenner will be the first confirmed, full-fledged CMS administrator since Mark McClellan, MD, PhD, stepped down from that position in October 2006, during the George W. Bush administration. Dr. McClellan's successors either were acting administrators or, in the case of Donald Berwick, MD, who was Tavenner's immediate predecessor, a recess appointment. As illustrated by Dr. Berwick's  CMS history , Senate confirmation can be tough to get when one party has enough votes to filibuster and otherwise stymie a nomination by an opposing party's president. That was the case when Obama nominated Dr. Berwick, whom Senate Republicans portrayed as an advocate of healthcare rationing, a characterization denied by t...
Post a Comment
Read more

Secondary Prevention: Clinical Approaches to Managing the Higher-Risk Patient with Heart Disease

INCIDENCE/PREVALENCE/BURDENS ASSOCIATED WITH CARDIOVASCULAR DISEASE (CVD) The prevention of an initial and recurrent cardiovascular event and other complications, such as diabetes and kidney failure [also known as end-stage renal disease (ESRD) or chronic kidney disease (CKD) stage 5] is an important goal in patients with a history of CVD. Each year, approximately 185,000 Americans suffer a recurrent stroke, approximately 470,000 will have a recurrent coronary attack, and an estimated 325,000 will suffer a recurrent myocardial infarction. [1]  Secondary prevention strategies offer the opportunity to prevent further complications and improve outcomes by early detection and management of common comorbidities. The burden on public health and the costs associated with chronic illnesses such as CVD, CKD, and diabetes remain high. An estimated 82.6 million American adults (1 in 3) have 1 or more types of CVD. [1]  Heart failure is the fastest-growing clinical cardiac disease ...
Post a Comment
Read more